Ann: CMO Appointment and Clinical Trials Update, page-7

I’ve just read this announcement & how fantastic for us to have Prof Packham on board as CMO & also heading our medical advisory board.

His credentials are exceptional as a nephrologist, both as a physician and his 30+ years of experience in clinical trials. Welcome David if you are reading this. Sure you wouldn’t have much time lately.

Clearly Team DXB have been so busy crossing every t & dotting every i in reviewing 2a, planning & implementing trial designs & carefully choosing sites for trials & participants for 2b trials. That sounds so simple...I can just imagine the complexities, particularly the synergies between both FSGS & diabetic nephropathy trials, that was mentioned more than once in the announcement.

Really looking forward to seeing this all unfold & come to fruition in the coming months. Particularly that FSGS mostly affects kids & adolescents. They still have their whole life ahead of them, and if this can make a massive difference, all the better.

Ps we had a great time at the Sydney Royal Easter Show today.